Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronobiology-timed antibiotic administration for Clostridioides difficile infection
MOH_2021-06-13_010042Phase 2Not yet recruiting
- Sponsor
- ד"ר דנה דרור
- Start
- May 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vancomycin and metronidazole in Clostridioides difficile colitis (CDI) (2 arms), sponsored by ד"ר דנה דרור. Primary endpoint: Recurrence of Clostridioides difficile infection. Planned start May 2021; status: not yet recruiting.
02
Drugs
vancomycinmetronidazole
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on MOH_2021-06-13_010042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-13_010042.